News
AXGN
8.07
+3.86%
0.30
Weekly Report: what happened at AXGN last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at AXGN last week (0311-0315)?
Weekly Report · 03/18 11:37
Weekly Report: what happened at AXGN last week (0304-0308)?
Weekly Report · 03/11 11:33
New Accounting & Financial Operations Risk for AxoGen – What’s the Latest?
TipRanks · 03/07 06:01
Axogen’s Strong Growth Prospects and Positive Analyst Outlook Prompt Buy Rating and Increased Price Target
TipRanks · 03/07 04:17
AxoGen files $100M mixed securities shelf
Seeking Alpha · 03/06 17:31
U.S. RESEARCH ROUNDUP-Arrivent Biopharma, Ferguson, Target
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Arrivent Biopharma, Ferguson and Target among companies with revised targets. Ferguson, Target and Box are among the companies with new analyst coverage. Analysts raised their ratings on Arrivent, Ferguson, and Target.
Reuters · 03/06 06:47
Buy Rating Affirmed: AxoGen’s Robust Growth and Market Potential Drive Positive Outlook
TipRanks · 03/06 05:35
AxoGen Inc reports results for the quarter ended in December - Earnings Summary
AxoGen Inc reports results for the quarter ended in December. Revenue rose 18.7% to $42.92 million from a year ago. The company reported a quarterly adjusted loss of 6 cents per share. AxoGen shares had risen by 55.1% this quarter.
Reuters · 03/05 23:41
AxoGen Releases Updated Corporate Presentation Online
TipRanks · 03/05 21:43
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
SOPHiA GENETICS SA shares tumbled 19% to $4.55 on Tuesday. The company reported worse than expected fourth-quarter earnings and issued 2024 guidance. Sunshine Biopharma, Inc. Shares rose 146.3% after dipping 19% on Monday.
Benzinga · 03/05 18:11
Axogen Shares Fall 13% on Lukewarm 2024 Outlook
Shares of Axogen fell 13% to $9.17 on Tuesday. The company guided for revenue growth that is cooler than expected for fiscal 2024. Shares remain up 34% year to date. Axogen makes surgical solutions for peripheral nerve injuries. The Florida-based company reported fourth-quarter earnings above analysts' expectations.
Dow Jones · 03/05 16:37
*Correct: Axogen 4Q Rev $42.9M, Not $159M
Dow Jones · 03/05 16:37
AxoGen Unveils Q4 and Full Year 2023 Financial Results
TipRanks · 03/05 12:32
AxoGen Non-GAAP EPS of -$0.06 beats by $0.02, revenue of $42.9M beats by $1.9M
Q4 non-GAAP EPS of -$0.06 beats by $0.02, revenue of $42.9M beats by 18.5%. 2024 Financial Guidance: AxoGen expects revenue to be in the range of $177 million to $181 million.
Seeking Alpha · 03/05 12:04
*Axogen Sees 2024 Rev $177M-$181M >AXGN
Dow Jones · 03/05 12:02
*Axogen 4Q Rev $159M >AXGN
Dow Jones · 03/05 12:01
BRIEF-AxoGen Q4 Gross Margin 78.7%
Reuters · 03/05 12:00
Press Release: Axogen, Inc Reports 2023 Fourth -2-
Will be approved in mid-2025, the expected timing of the launch of Avive+ Soft Tissue Matrix. Forward-looking statements are not a guarantee of future performance. Axogen uses the non-GAAP financial measures of EBITDA to supplement its financial statements.
Dow Jones · 03/05 12:00
Press Release: Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
Axogen, Inc. Reports 2023 Fourth Quarter and Full-Year Financial Results. Fourth quarter revenue was $42.9 million, an 18.7% increase over the fourth quarter of 2022. Full-year revenue for the year was $159.0 million. The Company is a leader in developing innovative surgical solutions for peripheral nerve injuries.
Dow Jones · 03/05 12:00
More
Webull provides a variety of real-time AXGN stock news. You can receive the latest news about Axogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About AXGN
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.